LifeStance Health Group Reports Strong Q3 2026 Results and Raises Full-Year Guidance
LifeStance Health Group (LFST) delivered robust third-quarter results for 2026, characterized by a 25% year-over-year revenue increase to $455.9 million. Growth was primarily driven by higher visit volumes and increased revenue per visit, reaching $170. The company's adjusted EBITDA surged 70% to $68.4 million, representing a 15.0% margin. Following the strong quarterly performance, management raised its full-year 2026 guidance for revenue, adjusted EBITDA, and center margin. While the company is seeing significant expansion in specialty services like TMS and Spravato, leadership cautioned that the transition to a new Electronic Health Record (EHR) platform may create a 1% to 2% headwind for revenue growth in 2027.
Tickers: $LFST
Topics: Clinician Productivity EBITDA Healthcare Services Net Income Revenue Growth